Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Despite its enduring relevance as the single most effective and important evidence-based treatment for schizophrenia, underutilization of clozapine remains considerable. To a substantial degree, this is attributable to a reluctance of psychiatrists to offer clozapine due to its relatively large side...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-03-01
|
| Series: | Therapeutic Advances in Psychopharmacology |
| Online Access: | https://doi.org/10.1177/20451253231158152 |
| _version_ | 1797860194766553088 |
|---|---|
| author | Mishal Qubad Robert A. Bittner |
| author_facet | Mishal Qubad Robert A. Bittner |
| author_sort | Mishal Qubad |
| collection | DOAJ |
| description | Despite its enduring relevance as the single most effective and important evidence-based treatment for schizophrenia, underutilization of clozapine remains considerable. To a substantial degree, this is attributable to a reluctance of psychiatrists to offer clozapine due to its relatively large side-effect burden and the complexity of its use. This underscores the necessity for continued education regarding both the vital nature and the intricacies of clozapine treatment. This narrative review summarizes all clinically relevant areas of evidence, which support clozapine’s wide-ranging superior efficacy – for treatment-resistant schizophrenia (TRS) and beyond – and make its safe use eminently feasible. Converging evidence indicates that TRS constitutes a distinct albeit heterogeneous subgroup of schizophrenias primarily responsive to clozapine. Most importantly, the predominantly early onset of treatment resistance and the considerable decline in response rates associated with its delayed initiation make clozapine an essential treatment option throughout the course of illness, beginning with the first psychotic episode. To maximize patients’ benefits, systematic early recognition efforts based on stringent use of TRS criteria, a timely offer of clozapine, thorough side-effect screening and management as well as consistent use of therapeutic drug monitoring and established augmentation strategies for suboptimal responders are crucial. To minimize permanent all-cause discontinuation, re-challenges after neutropenia or myocarditis should be considered. Owing to clozapine’s unique efficacy, comorbid conditions including substance use and most somatic disorders should not dissuade but rather encourage clinicians to consider clozapine. Moreover, treatment decisions need to be informed by the late onset of clozapine’s full effects, which for reduced suicidality and mortality rates may not even be readily apparent. Overall, the singular extent of its efficacy combined with the high level of patient satisfaction continues to distinguish clozapine from all other available antipsychotics. |
| first_indexed | 2024-04-09T21:42:24Z |
| format | Article |
| id | doaj.art-03856194e61e4e5fbf1595fa8fe64ff5 |
| institution | Directory Open Access Journal |
| issn | 2045-1261 |
| language | English |
| last_indexed | 2024-04-09T21:42:24Z |
| publishDate | 2023-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Psychopharmacology |
| spelling | doaj.art-03856194e61e4e5fbf1595fa8fe64ff52023-03-26T05:03:22ZengSAGE PublishingTherapeutic Advances in Psychopharmacology2045-12612023-03-011310.1177/20451253231158152Second to none: rationale, timing, and clinical management of clozapine use in schizophreniaMishal QubadRobert A. BittnerDespite its enduring relevance as the single most effective and important evidence-based treatment for schizophrenia, underutilization of clozapine remains considerable. To a substantial degree, this is attributable to a reluctance of psychiatrists to offer clozapine due to its relatively large side-effect burden and the complexity of its use. This underscores the necessity for continued education regarding both the vital nature and the intricacies of clozapine treatment. This narrative review summarizes all clinically relevant areas of evidence, which support clozapine’s wide-ranging superior efficacy – for treatment-resistant schizophrenia (TRS) and beyond – and make its safe use eminently feasible. Converging evidence indicates that TRS constitutes a distinct albeit heterogeneous subgroup of schizophrenias primarily responsive to clozapine. Most importantly, the predominantly early onset of treatment resistance and the considerable decline in response rates associated with its delayed initiation make clozapine an essential treatment option throughout the course of illness, beginning with the first psychotic episode. To maximize patients’ benefits, systematic early recognition efforts based on stringent use of TRS criteria, a timely offer of clozapine, thorough side-effect screening and management as well as consistent use of therapeutic drug monitoring and established augmentation strategies for suboptimal responders are crucial. To minimize permanent all-cause discontinuation, re-challenges after neutropenia or myocarditis should be considered. Owing to clozapine’s unique efficacy, comorbid conditions including substance use and most somatic disorders should not dissuade but rather encourage clinicians to consider clozapine. Moreover, treatment decisions need to be informed by the late onset of clozapine’s full effects, which for reduced suicidality and mortality rates may not even be readily apparent. Overall, the singular extent of its efficacy combined with the high level of patient satisfaction continues to distinguish clozapine from all other available antipsychotics.https://doi.org/10.1177/20451253231158152 |
| spellingShingle | Mishal Qubad Robert A. Bittner Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia Therapeutic Advances in Psychopharmacology |
| title | Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia |
| title_full | Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia |
| title_fullStr | Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia |
| title_full_unstemmed | Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia |
| title_short | Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia |
| title_sort | second to none rationale timing and clinical management of clozapine use in schizophrenia |
| url | https://doi.org/10.1177/20451253231158152 |
| work_keys_str_mv | AT mishalqubad secondtononerationaletimingandclinicalmanagementofclozapineuseinschizophrenia AT robertabittner secondtononerationaletimingandclinicalmanagementofclozapineuseinschizophrenia |